CompanyGraph
What stands out
- Dividend several times the last twelve months' earnings
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $88.55M, above the global median of $18.73M
- FinancialsAltman Z-Score 6.57: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Dividend several times the last twelve months' earnings
Dividends view
Yield
4.29%
Annual Rate
CNY 0.23Paid unknown
Payout Ratio
308.4%High
Payback Period
29.0 yr
Last Ex-Dividend
Mar 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.16BCNY471.16M · vs all stocks (USD)
Trailing P/E
88.83xRevenue (TTM)
972.17MCNY145.01M · vs all stocks (USD)
Profit Margin
3.94%Beta
0.1640xvs all stocks
52-Week Change
-11.96%vs all stocks
Forward Annual Dividend Yield
4.29%vs all stocks
Market Capitalization
3.16BCNY471.16M · vs all stocks (USD)
Enterprise Value
2.23BCNY332.48M · vs all stocks (USD)
Trailing P/E
88.83xPrice to Sales (TTM)
3.27xPrice to Book (MRQ)
2.09xEnterprise to Revenue
2.29xEnterprise to EBITDA
16.28xGross Margin
37.30%Profit Margin
3.94%Operating Margin
15.60%Return on Assets (TTM)
3.16%Return on Equity (TTM)
2.46%Revenue (TTM)
972.17MCNY145.01M · vs all stocks (USD)
Revenue per Share (TTM)
1.63CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-49.00%Gross Profit (TTM)
318.97MCNY47.58M · vs all stocks (USD)
EBITDA (TTM)
185.91MCNY27.73M · vs all stocks (USD)
Net Income (TTM)
38.26MCNY5.71M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-47.50%Operating Cash Flow (TTM)
606.54MCNY90.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
593.67MCNY88.55M · vs all stocks (USD)
Forward Annual Dividend Rate
0.2300CNYUpdated Sep 19, 2026Forward Annual Dividend Yield
4.29%vs all stocks
Trailing Annual Dividend Rate
0.1880CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
3.53%vs all stocks
Payout Ratio
308.41%Minority Interest (Equity)
-646.38KCNYFY2025 · Dec 31, 2025Revenue
1.48BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.07BCNYFY2025 · Dec 31, 2025Gross Profit
415.56MCNYFY2025 · Dec 31, 2025Operating Income
158.27MCNY23.61M · vs all stocks (USD)
Pre-tax Income
102.67MCNYFY2025 · Dec 31, 2025Income Tax Expense
19.78MCNYFY2025 · Dec 31, 2025Net Income
82.88MCNYFY2025 · Dec 31, 2025EBIT
105.05MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
185.91MCNYFY2025 · Dec 31, 2025Research & Development
26.86MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
106.22MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.84MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.64MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.38MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1391CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1391CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
595.85MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
595.85MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
82.88MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
662.36MCNYFY2025 · Dec 31, 2025Free Cash Flow
613.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
545.14MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
82.88MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.71MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
533.94MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
43.84MCNYFY2025 · Dec 31, 2025Capital Expenditures
-48.61MCNYFY2025 · Dec 31, 2025Purchase of Investments
-395.39MCNYFY2025 · Dec 31, 2025Sale of Investments
95.87MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-348.14MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-30.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-36.57MCNYFY2025 · Dec 31, 2025Other Financing Charges
-13.88MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-80.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
595.99MSharesUpdated Sep 19, 2026Float Shares
401.15MSharesUpdated Sep 19, 2026% Held by Insiders
33.71%vs all stocks
% Held by Institutions
0.58%vs all stocks
Total Cash (MRQ)
1.03BCNY153.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.73CNYUpdated Sep 19, 2026Total Debt (MRQ)
88.94MCNY13.27M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0586xCurrent Ratio (MRQ)
4.75xBook Value per Share (MRQ)
2.55CNYUpdated Sep 19, 2026Total Assets
1.99BCNY297.25M · vs all stocks (USD)
Total Current Assets
1.66BCNYFY2025 · Dec 31, 2025Total Liabilities
431.58MCNYFY2025 · Dec 31, 2025Total Non-current Assets
330.34MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
62.95MCNYFY2025 · Dec 31, 2025Total Current Liabilities
368.64MCNYFY2025 · Dec 31, 2025Cash
863.76MCNYFY2025 · Dec 31, 2025Cash Equivalents
45.54MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
909.30MCNYFY2025 · Dec 31, 2025Accounts Receivable
486.79MCNYFY2025 · Dec 31, 2025Inventory
134.61MCNYFY2025 · Dec 31, 2025Accounts Payable
192.17MCNYFY2025 · Dec 31, 2025Short-term Debt
19.56MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.27MCNYFY2025 · Dec 31, 2025Long-term Debt
3.54MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
43.11MCNYFY2025 · Dec 31, 2025Common Stock (Book)
595.99MCNYFY2025 · Dec 31, 2025Retained Earnings
679.78MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.56BCNY232.87M · vs all stocks (USD)
52-Week Low
4.66CNYUpdated Sep 19, 202652-Week High
7.99CNYUpdated Sep 19, 202652-Week Change
-11.96%vs all stocks
Beta
0.1640xvs all stocks
50-Day MA
5.46CNYUpdated Sep 19, 2026200-Day MA
5.89CNYUpdated Sep 19, 2026Avg 10-Day Volume
11.42MSharesUpdated Sep 19, 2026Avg 30-Day Volume
22.56MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.0600CNYUpdated Sep 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 3.08Dividend per Share: 0.19Earnings per Share: 0.06
Financial Health
Altman Z-Score 6.57: safe zoneNotable
Altman Z-Score: 6.57
High earnings qualityNotable
Earnings Quality Score: 1.14
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $88.55M, above the global median of $18.73MNotable
Levered free cash flow (USD): 88,551,361.367Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Fortune Electric Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total Debt
Sakura Development Co. Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total Debt
Hindustan Copper Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total Debt